Prolonged-release (PR) fampridine is the only approved medication to improve walking in multiple sclerosis (MS), having been shown to produce a clinically meaningful improvement in walking ability in the subset of MS patients with Expanded Disability Status Scale 4–7. Recent responder subgroup analyses in the phase III ENHANCE study show a large effect size in terms of an increase of 20.58 points on the patient-reported 12-item MS Walking Scale in the 43% of patients classified as responders to PR-fampridine, corresponding to a standardized response mean of 1.68. Use of PR-fampridine in clinical practice varies across Europe, depending partly on whether it is reimbursed. A group of European MS experts met in June 2017 to discuss their experience with using PR-fampridine, including their views on the patient population for treatment, assessment of treatment response, re-testing and re-treatment, and stopping criteria. This article summarizes the experts’ opinions on how PR-fampridine can be used in real-world clinical practice to optimize the benefits to people with MS with impaired walking ability.
Prolonged-release fampridine in multiple sclerosis. clinical data and real-world experience. report of an expert meeting / Albrecht, Philipp; Bjørnå, Ingrid Kristine; Brassat, David; Farrell, Rachel; Feys, Peter; Hobart, Jeremy; Hupperts, Raymond; Linnebank, Michael; Magdič, Jožef; Oreja-Guevara, Celia; Pozzilli, Carlo; Salgado, Antonio Vasco; Ziemssen, Tjalf. - In: THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS. - ISSN 1756-2856. - 11:(2018), pp. 1-8. [10.1177/1756286418803248]
Prolonged-release fampridine in multiple sclerosis. clinical data and real-world experience. report of an expert meeting
Pozzilli, Carlo;
2018
Abstract
Prolonged-release (PR) fampridine is the only approved medication to improve walking in multiple sclerosis (MS), having been shown to produce a clinically meaningful improvement in walking ability in the subset of MS patients with Expanded Disability Status Scale 4–7. Recent responder subgroup analyses in the phase III ENHANCE study show a large effect size in terms of an increase of 20.58 points on the patient-reported 12-item MS Walking Scale in the 43% of patients classified as responders to PR-fampridine, corresponding to a standardized response mean of 1.68. Use of PR-fampridine in clinical practice varies across Europe, depending partly on whether it is reimbursed. A group of European MS experts met in June 2017 to discuss their experience with using PR-fampridine, including their views on the patient population for treatment, assessment of treatment response, re-testing and re-treatment, and stopping criteria. This article summarizes the experts’ opinions on how PR-fampridine can be used in real-world clinical practice to optimize the benefits to people with MS with impaired walking ability.File | Dimensione | Formato | |
---|---|---|---|
Albrecht_prolonged-release-fampridine_2018.pdf
solo gestori archivio
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Creative commons
Dimensione
448.93 kB
Formato
Adobe PDF
|
448.93 kB | Adobe PDF | Contatta l'autore |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.